Salinomycin exerts anti-colorectal cancer activity by targeting the β-catenin/T-cell factor complex.

Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE

Publication: London : Wiley
Original Publication: London, Macmillian Journals Ltd.

Antineoplastic Agents/*pharmacology ; Colorectal Neoplasms/*drug therapy ; Pyrans/*pharmacology ; TCF Transcription Factors/*antagonists & inhibitors ; beta Catenin/*antagonists & inhibitors; Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cells, Cultured ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; HEK293 Cells ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Pyrans/chemical synthesis ; Pyrans/chemistry ; Signal Transduction/drug effects ; Structure-Activity Relationship ; TCF Transcription Factors/metabolism ; beta Catenin/metabolism

Background and Purpose: Salinomycin is a well-known inhibitor of human cancer stem cells (CSCs). However, the molecular mechanism(s) by which salinomycin targets colorectal CSCs is poorly understood. Here, we have investigated underlying antitumour mechanisms of salinomycin in colorectal cancer cells and three tumour models.
Experimental Approach: The inhibitory effect of salinomycin on the Wnt/β-catenin pathway was analysed with the SuperTopFlash reporter system. The mRNA expression of Wnt target genes was evaluated with real-time PCR. Effects of salinomycin on β-catenin/TCF4E interaction were examined using co-immunoprecipitation and an in vitro GST pull-down assay. Cell proliferation was determined by BrdU incorporation and soft agar colony formation assay. The stemness of the cells was assessed by sphere formation assay. Antitumour effects of salinomycin on colorectal cancers was evaluated with colorectal CSC xenografts, APC ^min/+ transgenic mice, and patient-derived colorectal tumour xenografts.
Key Results: Salinomycin blocked β-catenin/TCF4E complex formation in colorectal cancer cells and in an in vitro GST pull-down assay, thus decreasing expression of Wnt target genes. Salinomycin also suppressed the transcriptional activity mediated by β-catenin/LEF1 or β-catenin/TCF4E complex and exhibited an inhibitory effect on the sphere formation, proliferation, and anchorage-independent growth of colorectal cancer cells. In colorectal tumour xenografts and APC ^min/+ transgenic mice, administration of salinomycin significantly reduced tumour growth and the expression of CSC-related Wnt target genes including LGR5.
Conclusions and Implications: Our study suggested that salinomycin could suppress the growth of colorectal cancer by disrupting the β-catenin/TCF complex and thus may be a promising agent for colorectal cancer treatment.
(© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Oncotarget. 2011 Aug;2(8):587. (PMID: 21860066)
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (PMID: 29149325)
Br J Pharmacol. 2019 Sep;176(17):3390-3406. (PMID: 31236922)
Clin Cancer Res. 2004 Apr 15;10(8):2790-6. (PMID: 15102686)
Cell. 2012 Jun 8;149(6):1192-205. (PMID: 22682243)
PLoS One. 2014 Sep 05;9(9):e107013. (PMID: 25192390)
Nature. 2007 Oct 25;449(7165):1003-7. (PMID: 17934449)
Ann Transl Med. 2016 Dec;4(24):508. (PMID: 28149870)
BMC Cancer. 2012 Nov 24;12:556. (PMID: 23176396)
Expert Opin Ther Targets. 2014 Jun;18(6):611-5. (PMID: 24702624)
Ann Surg Oncol. 2011 Jun;18(6):1797-804. (PMID: 21267784)
Cell. 2009 Aug 21;138(4):645-659. (PMID: 19682730)
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7. (PMID: 21788521)
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):90-100. (PMID: 21293509)
J Natl Cancer Inst. 2017 Aug 1;109(8):. (PMID: 28423402)
Oman Med J. 2010 Apr;25(2):79-87. (PMID: 22125706)
Am J Pathol. 1999 Feb;154(2):515-23. (PMID: 10027409)
Austin J Pharmacol Ther. 2014;2(3):1020. (PMID: 25478603)
Clin Cancer Res. 2011 Feb 15;17(4):647-53. (PMID: 21159886)
World J Gastroenterol. 2008 Oct 21;14(39):6052-9. (PMID: 18932285)
PLoS One. 2019 Feb 14;14(2):e0211916. (PMID: 30763370)
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E89-98. (PMID: 24367099)
J Biomed Biotechnol. 2012;2012:950658. (PMID: 23251084)
Dev Biol. 2007 May 15;305(2):498-507. (PMID: 17397822)
Cell. 2002 Oct 18;111(2):241-50. (PMID: 12408868)
Br J Pharmacol. 2018 Apr;175(7):987-993. (PMID: 29520785)
BMC Cancer. 2016 Nov 17;16(1):896. (PMID: 27855654)
Nat Med. 2017 Oct 6;23(10):1124-1134. (PMID: 28985214)
Biomark Med. 2015;9(4):349-61. (PMID: 25808439)
Neuron. 2005 Apr 7;46(1):23-36. (PMID: 15820691)
Nat Med. 2015 Nov;21(11):1318-25. (PMID: 26479923)
Biochem Biophys Res Commun. 2010 Apr 16;394(4):1098-104. (PMID: 20350531)
Nat Cell Biol. 2010 May;12(5):468-76. (PMID: 20418870)
Br J Pharmacol. 2017 Dec;174(24):4589-4599. (PMID: 28752891)
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359. (PMID: 29055034)
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13150-13155. (PMID: 27799526)
Nat Rev Drug Discov. 2014 Jul;13(7):513-32. (PMID: 24981364)
Br J Pharmacol. 2010 Aug;160(7):1577-9. (PMID: 20649561)
J Cell Biochem. 2014 Oct;115(10):1799-807. (PMID: 24905570)
Invest New Drugs. 2012 Aug;30(4):1311-8. (PMID: 21573958)
PLoS One. 2013 Jul 01;8(7):e69086. (PMID: 23840907)
Oncogene. 2017 Mar;36(11):1461-1473. (PMID: 27617575)
Br J Pharmacol. 2018 Feb;175(3):407-411. (PMID: 29350411)
Nature. 2012 Jul 18;487(7407):330-7. (PMID: 22810696)
Tumour Biol. 2017 Mar;39(3):1010428317695035. (PMID: 28349817)
Nature. 2017 May 11;545(7653):187-192. (PMID: 28355176)
J Mol Med (Berl). 2014 Aug;92(8):889-900. (PMID: 24770997)
Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129. (PMID: 29055040)
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7522-E7531. (PMID: 30038030)
Stem Cells. 2012 Nov;30(11):2378-86. (PMID: 22969042)
Chem Biol Interact. 2015 Feb 25;228:100-7. (PMID: 25499043)
Eur Rev Med Pharmacol Sci. 2016 May;20(10):2045-51. (PMID: 27249603)
J Clin Pathol. 2018 Feb;71(2):110-116. (PMID: 28942428)
Mol Cancer Res. 2013 Mar;11(3):207-18. (PMID: 23339186)
Oncol Rep. 2012 Oct;28(4):1301-8. (PMID: 22895640)
AAPS PharmSciTech. 2015 Aug;16(4):731-41. (PMID: 26070545)
Mol Cancer. 2010 Aug 06;9:212. (PMID: 20691072)
Oncotarget. 2016 May 3;7(18):26580-92. (PMID: 27058891)
Cancer Res. 2016 Feb 15;76(4):891-901. (PMID: 26645562)
Br J Pharmacol. 2017 Dec;174 Suppl 1:S360-S446. (PMID: 29055035)
Br J Pharmacol. 2015 Jul;172(13):3189-93. (PMID: 25964986)
Cell. 2017 Jun 1;169(6):985-999. (PMID: 28575679)

0 (Antineoplastic Agents)
0 (CTNNB1 protein, human)
0 (Pyrans)
0 (TCF Transcription Factors)
0 (beta Catenin)
62UXS86T64 (salinomycin)

Date Created: 20190626 Date Completed: 20200828 Latest Revision: 20240719

20240719

PMC6692576

10.1111/bph.14770

31236922